Evidence map›Paper›PMID 32961244›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021

Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.

Jennifer E Flythe, Magdalene M Assimon, Matthew J Tugman, Emily H Chang, Shruti Gupta, Jatan Shah, Marie Anne Sosa, Amanda DeMauro Renaghan, Michal L Melamed, F Perry Wilson and 9 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 139 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04343898 completednot on this map

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

TypeobservationalSponsorBrigham and Women's HospitalRan2020 to 2023Enrolled5,154ConditionsCoronavirus InfectionArmsNo intervention
NCT04706533 completednot on this map

Prospective Observational Study Examining Clinical Characteristics, Inflammatory Markers, Treatments and Outcomes of Patients Hospitalized for COVID-19 at the University of Michigan Healthcare System in Ann Arbor

TypeobservationalSponsorUniversity of MichiganRan2020 to 2022Enrolled3,402ConditionsCovid19, Kidney Diseases, Inflammation, SARS-CoV InfectionArmsBiomarkers of inflammation
3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 3 syntheses or guidelines pooled it, 231 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 14 institutions in 1 country.

Jennifer E FlytheDivision of Nephrology and Hypertension, Department of Medicine, University of North Carolina (UNC) Kidney Center, UNC School of Medicine, Chapel Hill, NC; Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC. Electronic address: jflythe@med.unc.edu.
Magdalene M AssimonDivision of Nephrology and Hypertension, Department of Medicine, University of North Carolina (UNC) Kidney Center, UNC School of Medicine, Chapel Hill, NC.
Matthew J TugmanDivision of Nephrology and Hypertension, Department of Medicine, University of North Carolina (UNC) Kidney Center, UNC School of Medicine, Chapel Hill, NC.
Emily H ChangDivision of Nephrology and Hypertension, Department of Medicine, University of North Carolina (UNC) Kidney Center, UNC School of Medicine, Chapel Hill, NC.
Shruti GuptaDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Jatan ShahDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Marie Anne SosaDivision of Nephrology, Department of Medicine, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, FL.
Amanda DeMauro RenaghanDivision of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Michal L MelamedDepartment of Medicine/Nephrology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
F Perry WilsonSection of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, CT; Clinical and Translational Research Accelerator, Yale University School of Medicine, New Haven, CT.
Javier A NeyraDivision of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY.
Arash RashidiDivision of Nephrology and Hypertension, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH.
Suzanne M BoyleSection of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Shuchi AnandDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.
Marta ChristovDivision of Nephrology, Department of Medicine, Westchester Medical Center, Valhalla, NY.
Leslie F ThomasDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic in Arizona, Scottsdale, AZ.
Daniel EdmonstonDivision of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Renal Section, Durham VA Medical Center, Durham, NC.
David E LeafDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
STOP-COVID Investigators
Brigham and Women's Hospital · USAlbert Einstein College of Medicine · USDuke University · USMayo Clinic in Arizona · USMedical College of Wisconsin · USStanford University · USTemple University · USUniversity Hospitals of Cleveland · USUniversity of Kentucky · USUniversity of Miami · USUniversity of North Carolina at Chapel Hill · USUniversity of Virginia Health System · USWestchester Medical Center · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The Institute for Translational MedicineUL1TR002389 · NCATS · UNIVERSITY OF CHICAGO · PI Joshua J Jacobs, DAVID O MELTZER · 2017 to 2026
$71.6M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Deferoxamine for the Prevention of Acute Kidney InjuryR01DK125786 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI LEAF, DAVID EVAN · 2020 to 2024
$3.5M
Optimizing Electronic Alerts for Acute Kidney InjuryR01DK113191 · NIDDK · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2018 to 2022
$3.1M
QT prolonging medications and sudden cardiac death among individuals on hemodialysisR01HL152034 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FLYTHE, JENNIFER E · 2020 to 2024
$2.8M
Role of SuPAR in the Intersection between Cardiovascular and Kidney DiseaseR01HL153384 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAYEK, SALIM · 2020 to 2024
$2.5M
Precision Medicine Approach to Vitamin D3 Administration in Critical IllnessR01HL144566 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEAF, DAVID EVAN · 2019 to 2022
$1.8M
Non-Invasive Imaging Biomarkers to Identify a High-Risk Chronic Kidney Disease PhenotypeK23DK120811 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SRIVASTAVA, ANAND · 2020 to 2024
$1.0M
Investigating strategies to reduce fluid-related complications among hemodialysis patientsK23DK109401 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FLYTHE, JENNIFER E · 2016 to 2020
$992k
The Assessment of Acute Kidney Injury Sub-phenotypes in the Intensive Care UnitK23DK116967 · NIDDK · UNIVERSITY OF WASHINGTON · PI BHATRAJU, PAVAN KUMAR · 2019 to 2023
$938k
Epidemiology and management of chronic kidney disease in South AsiansK23DK101826 · NIDDK · STANFORD UNIVERSITY · PI ANAND, SHUCHI · 2014 to 2018
$919k
NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002389NHLBI NIH HHS K23 HL130648NHLBI NIH HHS K23 HL143053NHLBI NIH HHS R01 HL144566NHLBI NIH HHS R01 HL152034NHLBI NIH HHS R01 HL153384NIDDK NIH HHS K23 DK101826NIDDK NIH HHS K23 DK109401NIDDK NIH HHS K23 DK116967NIDDK NIH HHS K23 DK120811NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK113191NIDDK NIH HHS R01 DK125786
6 · The paper itself

Abstract

RATIONALE &

objectiveUnderlying kidney disease is an emerging risk factor for more severe coronavirus disease 2019 (COVID-19) illness. We examined the clinical courses of critically ill COVID-19 patients with and without pre-existing chronic kidney disease (CKD) and investigated the association between the degree of underlying kidney disease and in-hospital outcomes. STUDY

designRetrospective cohort study. SETTINGS &

participants4,264 critically ill patients with COVID-19 (143 patients with pre-existing kidney failure receiving maintenance dialysis; 521 patients with pre-existing non-dialysis-dependent CKD; and 3,600 patients without pre-existing CKD) admitted to intensive care units (ICUs) at 68 hospitals across the United States. PREDICTOR(S): Presence (vs absence) of pre-existing kidney disease. OUTCOME(S): In-hospital mortality (primary); respiratory failure, shock, ventricular arrhythmia/cardiac arrest, thromboembolic events, major bleeds, and acute liver injury (secondary). ANALYTICAL APPROACH: We used standardized differences to compare patient characteristics (values>0.10 indicate a meaningful difference between groups) and multivariable-adjusted Fine and Gray survival models to examine outcome associations.

resultsDialysis patients had a shorter time from symptom onset to ICU admission compared to other groups (median of 4 [IQR, 2-9] days for maintenance dialysis patients; 7 [IQR, 3-10] days for non-dialysis-dependent CKD patients; and 7 [IQR, 4-10] days for patients without pre-existing CKD). More dialysis patients (25%) reported altered mental status than those with non-dialysis-dependent CKD (20%; standardized difference=0.12) and those without pre-existing CKD (12%; standardized difference=0.36). Half of dialysis and non-dialysis-dependent CKD patients died within 28 days of ICU admission versus 35% of patients without pre-existing CKD. Compared to patients without pre-existing CKD, dialysis patients had higher risk for 28-day in-hospital death (adjusted HR, 1.41 [95% CI, 1.09-1.81]), while patients with non-dialysis-dependent CKD had an intermediate risk (adjusted HR, 1.25 [95% CI, 1.08-1.44]). LIMITATIONS: Potential residual confounding.

conclusionsFindings highlight the high mortality of individuals with underlying kidney disease and severe COVID-19, underscoring the importance of identifying safe and effective COVID-19 therapies in this vulnerable population.

Indexed as

COVID-19Critical IllnessRenal Insufficiency, ChronicAgedComorbidityFemaleHospital MortalityHumansIntensive Care UnitsKidney Function TestsMaleRenal DialysisRetrospective StudiesRisk FactorsSARS-CoV-2Treatment Outcomealtered mental statuschronic kidney disease (CKD)clinical courseclinical trajectoryCoronavirus disease 2019 (COVID-19)COVID-19 outcomecritical illnessdialysisend-stage kidney disease (ESKD)end-stage renal disease (ESRD)glomerular filtration rate (GFR)in-hospital mortalityintensive care unit (ICU)prognosisrenal functionsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)severe COVID-19

Identifiers

PMID32961244
PMCPMC7501875
OpenAlexW3087645946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.